Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.
Junjun LiMengjiao LanJin PengQunli XiongYongfeng XuYang YangYing ZhouJinlu LiuZhu ZengXiaojuan YangZhiwei ZhangPumin ZhangQing ZhuWei WuPublished in: Genes (2022)
Triple-negative breast cancer (TNBC) is a type of breast tumor that currently lacks options for targeted therapy. Tremendous effort has been made to identify treatment targets for TNBC. Here, we report that the expression level of anaphase promoting complex (APC) coactivator Cdh1 in TNBC is elevated compared to that in the adjacent healthy tissues, and high levels of Cdh1 expression are correlated with poor prognoses, suggesting that Cdh1 contributes to the progression of TNBC. Interfering with the function of Cdh1 can potentiate the cytotoxic effects of PARP inhibitors against BRCA-deficient and BRCA-proficient TNBC cells through inducing DNA damage, checkpoint activation, cell cycle arrest, and apoptosis. Further investigation reveals that Cdh1 promotes BRCA1 foci formation and prevents untangled DNA entering mitosis in response to PARP inhibition (PARPi) in TNBC cells. Collectively, these results suggest that APC/Cdh1 is a potential molecular target for PARPi-based therapies against TNBCs.
Keyphrases
- cell cycle arrest
- dna damage
- cell death
- induced apoptosis
- pi k akt
- oxidative stress
- dna repair
- endoplasmic reticulum stress
- poor prognosis
- signaling pathway
- gene expression
- binding protein
- cell cycle
- cell proliferation
- circulating tumor
- mouse model
- smoking cessation
- replacement therapy
- circulating tumor cells
- nucleic acid